GELITA will present its latest excipient innovations for the pharmaceutical and medical device industries at COMPAMED 2025.
As an acknowledged expert in pharmaceutical gelatin and collagen peptides, GELITA is taking excipient technology to the next level with solutions that combine safety, performance and sustainability.
At COMPAMED, GELITA will highlight the following solutions from its Endotoxin Controlled Excipients (ECE) portfolio:
- MEDELLAPRO (gelatin): a highly versatile excipient recognised for its inherent biocompatibility and formulation flexibility. Key applications include surgical sealants, hemostatic agents, scaffolds and advanced drug delivery systems.
- VACCIPRO (collagen peptides): a trusted stabiliser for vaccines and injectables, offering low allergenic potential, high tolerability and excellent cell and tissue compatibility.
Both excipients are designed to meet the demanding needs of sensitive medical applications such as vaccine stabilisation, tissue engineering, advanced wound care, implants, cell culturing and 3D bioprinting.
In these applications, safety and consistent quality are paramount.
GELITA’s rigorous endotoxin control standards support the highest levels of product safety and regulatory compliance.
The MEDELLAPRO gelatin line will be extended by a NEW product with less than 10 endotoxin units per gram.
Beyond its established portfolio, GELITA is investing heavily in biotechnology to develop animal-free collagen alternatives.
These innovations aim to deliver optimised functionality while improving sustainability and regulatory compliance, ensuring that tomorrow’s excipients meet the evolving requirements of both the pharmaceutical industry and society.
COMPAMED attendees are invited to visit GELITA at Booth 8A S20 to explore how MEDELLAPRO and VACCIPRO are shaping the future of excipient science, medical devices and vaccine technologies.